Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 1, 2014, Pages 13-19

  Hong, David I ^a,b   Dioun, Anahita F ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adult; Allergy; Chemotherapeutic agent; Drug challenge; Drug desensitization; Hypersensitivity reactions; Monoclonal antibody; Pediatric; Skin testing

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; HISTAMINE; MONOCLONAL ANTIBODY; MONTELUKAST; PARACETAMOL; RANITIDINE;

ALLERGIC REACTION; ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; DESENSITIZATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; HUMAN; INFORMED CONSENT; LABORATORY TEST; LOW DRUG DOSE; MEDICAL HISTORY; MORNING DOSAGE; OUTCOME ASSESSMENT; PREMEDICATION; PRURITUS; RISK FACTOR; SINGLE DRUG DOSE; SKIN TEST; TREATMENT INDICATION;

ADULT; ALLERGY; CHEMOTHERAPEUTIC AGENT; DRUG CHALLENGE; DRUG DESENSITIZATION; HSR; HYPERSENSITIVITY REACTION; HYPERSENSITIVITY REACTIONS; MAB; MONOCLONAL ANTIBODY; PEDIATRIC; SKIN TESTING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; HUMANS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN TESTS; TREATMENT OUTCOME;

EID: 84891644010     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.11.007     Document Type: Article

References (31)

1. Limsuwan T., Castells M.C. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf 2010, 9:39-53.
2. Ruggiero A., Triarico S., Trombatore G., Battista A., Dell'acqua F., Rizzari C., et al. Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer. Eur J Clin Pharmacol 2013, 69:1739-1746.
3. Cernadas J.R., Brockow K., Romano A., Aberer W., Torres M.J., Bircher A., et al. General considerations on rapid desensitization for drug hypersensitivity: a consensus statement. Allergy 2010, 65:1357-1366.
4. Kim R.J., Peterson G., Kulp B., Zanotti K.M., Markman M. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 2005, 97:374-378.
5. Lotem M., Lyass O., Goldenhersh M.A., Ingber A., Peretz T., Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000, 136:1475-1480.
6. Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007, 18:1159-1164.
7. Dioun A.F. Management of multiple drug allergies in children. Curr Allergy Asthma Rep 2012, 12:79-84.
8. Zanotti K.M., Rybicki L.A., Kennedy A.W., Belinson J.L., Webster K.D., Kulp B., et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001, 19:3126-3129.
9. Leguy-Seguin V., Jolimoy G., Coudert B., Pernot C., Dalac S., Vabres P., et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007, 119:726-730.
10. Castells M.C., Tennant N.M., Sloane D.E., Hsu F.I., Barrett N.A., Hong D.I., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008, 122:574-580.
11. Brennan P.J., Rodriguez Bouza T., Hsu F.I., Sloane D.E., Castells M.C. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009, 124:1259-1266.
12. Matucci A., Pratesi S., Petroni G., Nencini F., Virgili G., Milla M., et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 2013, 43:659-664.
13. Brown S.G. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004, 114:371-376.
14. Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004, 24:425-443. vi.
15. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010, 105:259-273. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and ImmunologyAmerican Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and ImmunologyAmerican College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and ImmunologyJoint Council of Allergy, Asthma and Immunology.
16. Lee C.W., Matulonis U.A., Castells M.C. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005, 99:393-399.
17. Breslow R.G., Caiado J., Castells M.C. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 2009, 102:155-160.
18. Vultaggio A., Maggi E., Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 2011, 11:262-268.
19. Goldberg A., Confino-Cohen R., Fishman A., Beyth Y., Altaras M. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996, 98:841-843.
20. Robinson J.B., Singh D., Bodurka-Bevers D.C., Wharton J.T., Gershenson D.M., Wolf J.K. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001, 82:550-558.
21. Hong D.I., Bankova L., Cahill K.N., Kyin T., Castells M.C. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol 2012, 8:43-52.
22. Aydogan M., Yologlu N., Gacar G., Uyan Z.S., Eser I., Karaoz E. Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: increase in number of Treg cells after desensitization. J Allergy Clin Immunol 2013, 132:478-480.
23. Puchner T.C., Kugathasan S., Kelly K.J., Binion D.G. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001, 7:34-37.
24. Lieberman P., Nicklas R.A., Oppenheimer J., Kemp S.F., Lang D.M., Bernstein D.I., et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010, 126:477-480.
25. Lazzareschi I., Ruggiero A., Riccardi R., Attinà G., Colosimo C., Lasorella A. Hypersensitivity reactions to carboplatin in children. J Neurooncol 2002, 58:33-37.
26. Lafay-Cousin L., Sung L., Carret A.S., Hukin J., Wilson B., Johnston D.L., et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer 2008, 112:892-899.
27. Visitsunthorn N., Utsawapreechawong W., Pacharn P., Jirapongsananuruk O., Vichyanond P. Immediate type hypersensitivity to chemotherapeutic agents in pediatric patients. Asian Pac J Allergy Immunol 2009, 27:191-197.
28. MacGlashan D. Subthreshold desensitization of human basophils re-capitulates the loss of Syk and FcεRI expression characterized by other methods of desensitization. Clin Exp Allergy 2012, 42:1060-1070.
29. MacGlashan D., Vilariño N. Nonspecific desensitization, functional memory, and the characteristics of SHIP phosphorylation following IgE-mediated stimulation of human basophils. J Immunol 2006, 177:1040-1051.
30. Sancho-Serra M.C., Simarro M., Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. Eur J Immunol 2011, 41:1004-1013.
31. Lee C.W., Matulonis U.A., Castells M.C. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004, 95:370-376.